HealthTech 409A Valuation: Sub-Sector Differences
HealthTech encompasses a wide range of business models — from pure-play SaaS tools for providers to medical devices requiring FDA clearance. The appropriate 409A methodology depends heavily on the sub-sector.
Digital Health SaaS
Digital health companies selling software to hospitals, clinics, or directly to consumers on a subscription basis are valued similarly to enterprise SaaS:
- ARR multiple methodology using comparable digital health public companies
- Key comps include Veeva, Health Catalyst, Phreesia, Evolent Health
- Multiples typically 20–30% lower than pure enterprise SaaS due to longer sales cycles, complex procurement, and concentration risk (e.g., large hospital system dependence)
- HIPAA compliance infrastructure and data security costs are reflected in margin adjustments
MedTech and Device Companies
Medical device companies requiring 510(k) clearance or PMA approval face a distinct valuation framework:
- Pre-revenue devices are valued using probability-weighted future revenue scenarios adjusted for regulatory approval probability
- Revenue multiples for cleared/approved devices range from 2–6x, with premium for high-margin, recurring consumables businesses
- Clinical validation status and regulatory pathway are key risk factors
- Strategic acquirer comparables (Medtronic, Stryker, Abbott acquisitions) provide transaction multiple benchmarks
Reimbursement Model Impact
How a HealthTech product gets paid for has a significant impact on its valuation multiple:
- Insurance-covered / CMS reimbursed: Higher certainty of revenue but complex billing and collection; multiples similar to healthcare services
- Direct-to-consumer (DTC): Higher margin but customer acquisition costs are key risk; multiples depend on retention and LTV/CAC
- Enterprise SaaS to providers: Most predictable; ARR multiple methodology applies
- Value-based care: Shared savings arrangements create variable revenue; DCF with scenario analysis is appropriate